Review Articles

Epidemiology of Activated Protein C Resistance and Factor V Leiden Mutation in the Mediterranean Region

Mehrez M. Jadaon

Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Kuwait

Correspondence to: Mehrez M. Jadaon. Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Kuwait. P.O. Box 31470 – Sulaibekha 90805 – Kuwait. Tel.: (965) 6664 3485, Fax: (965) 2498 3835. Email: mehrez@hsc.edu.kw, mehrezmls99@yahoo.com

Competing interests: The authors have declared that no competing interests exist.

Published: September 8, 2011
Received: July 11, 2011
Accepted: August 17, 2011

Medit J Hematol Infect Dis 2011, 3: e2011037, DOI 10.4084/MJHID.2011.037
This article is available from: http://www.mjhid.org/article/view/8811
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract: Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and mortality rates. Many genetic and acquired risk factors were identified to cause VTE. The most common genetic risk factor is Factor V Leiden mutation (FVL). FVL was found in high percentage of populations of Caucasian origin but was almost absent in non-Caucasians. It was also reported in populations living in North Africa and the Middle East. This review article briefly explains FVL and how it causes VTE, the distribution of FVL worldwide, and then it elaborates on the epidemiology of FVL in the Mediterranean Region and how this brought speculations that FVL might have originated in the Eastern Mediterranean area.

Introduction: Thrombophilia is the term given to abnormal blood coagulation condition leading to increased tendency towards coagulation (hypercoagulability status). People with hypercoagulability are at risk of developing thrombosis, especially venous thromboembolic disorders (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is a significant cause of morbidity and mortality in many countries with an annual incidence of 1/1000.1-4 Many genetic and acquired risk factors for the development of VTE were identified. In fact, the WHO expert group (1996) defined thrombophilia as a tendency to develop VTE that may be genetically determined, acquired or both.5 Genetic factors include activated protein C resistance (APC-R) associated with Factor V Leiden mutation (FVL), Prothrombin G20210A mutation associated with high levels of prothrombin, genetic deficiencies of proteins C, S and antithrombin, and others. Acquired risk factors include lupus anticoagulants, pregnancy, use of contraceptives, major surgeries, cancer, inflammations, and others. This review article focuses on the epidemiology of APC-R/FVL in the Mediterranean area. For a better understanding of the pathophysiology involved in causing hypercoagulability by APC-R/FVL, it may be helpful to start by a quick revision of the process of coagulation and its associated natural anticoagulants.

Blood Coagulation: Normally, blood loss through injured vessels is prevented by a normal physiological process called “Hemostasis”. Normal human
The processes of coagulation and fibrinolysis as a series of chemical reactions leading to the formation of a clot to stop bleeding from the site of injury, and then removing the clot afterwards. Solid lines indicate activation process, while dashed lines indicate inactivation process. Abbreviations: antithrombin (AT), protein C (PC), activated protein C (APC), protein S (PS), phospholipids (PL), lupus anticoagulants (LA), tissue plasminogen activator (tPA), tPA inhibitor (tPAI), α2 antiplasmin (α2AP), thrombin activatable fibrinolysis inhibitor (TAFI).

Hemostasis is a balanced system which, on one hand, prevents excessive bleeding from any injured site, while on the other hand maintains blood circulation inside intact blood vessels by inhibiting intravascular coagulation. An efficient hemostatic process possesses intrinsic well-balanced regulatory systems, involving a number of dynamic mechanisms and chemical and physical reactions. It usually includes platelets, blood vessels and the coagulation system. In blood coagulation, a prominent response to an injury is recruited in the form of stepwise (cascade) chemical interactions leading to fibrin formation. This complex system involves certain proteins called the plasma clotting factors (enzymes). These enzymes circulate in the blood in an inactive form, and get activated in case of vessel injury. In summary, when a blood vessel is injured, the coagulation cascade is initiated by the release of tissue factor (thromboplastin) and the exposure of intravascular collagen, which activates clotting factors VII and XII, respectively. These clotting factors activate other clotting factors in a stepwise procedure ending up with the formation of a fibrin clot. A fibrin clot, in association with platelets, form a plug that blocks the injured blood vessel, preventing bleeding and allowing for wound healing. After healing, the fibrin clot is dissolved by the enzyme plasmin in a process called fibrinolysis. The whole process is under careful supervision by three main proteins that circulate normally in the blood; namely protein C (and its active form activated protein C; APC), protein S (PS) and antithrombin (AT). These so-called “natural anticoagulants” monitor the processes of coagulation and fibrinolysis in order to prevent excessive clotting. Abnormalities in clotting factors may lead to bleeding problems (hemophilia), while abnormalities in the natural anticoagulants may lead to
Activated Protein C Resistance and Factor V Leiden Mutation: In 1993, a Swedish research team led by B. Dahlbäck recognized an unusual phenomenon affecting the coagulation system. They were studying the effect of addition of external APC to plasma of patients with VTE. Normally, APC should inactivate clotting Factor V (FV) (Figure 1) and therefore slow down the coagulation process. However, in certain patients studied by Dahlbäck and his team, this slowing down did not occur. They called this phenomenon “APC resistance”, and they originally thought this could be due a deficiency in a yet unknown protein that co-helps APC in inactivating FV. One year later, another group of researchers from Holland, led by R. M. Bertina, discovered a missense point mutation in the FV gene, where adenine (A) replaced guanine (G) at nucleotide position 1691 of exon 10 of the FV gene, only eleven nucleotides upstream of the beginning of intron 10. They called this mutation as FV Leiden mutation (FVL) after the Dutch city where they made their discovery in. This nucleotide replacement happened to be in the codon for the amino acid residue arginine 506 (CGA) normally present in the factor V molecule, creating a new codon (CAA) which is translated as glutamine. In order to inactivate FV, APC needs to recognize arginine at position 506 of the FV molecule (Figure 2). Because of the amino acid change in FVL, APC can no longer inactivate FV efficiently, but FV retains its coagulation capabilities and therefore carriers of FVL develop hypercoagulability which may clinically manifest as VTE episodes. Later studies showed that people with FVL were at higher risk of developing VTE (10-fold in heterozygous carriers and 30 to 140-fold in homozygous carriers). In addition, most homozygotes for FVL were reported to get at least one VTE event in their life time. This explains the great clinical and scientific consideration this mutation had appealed and the hundreds of studies conducted on its prevalence and risk for developing VTE in almost every part of the world.

World Distribution of Factor V Leiden: Since its discovery, several studies were conducted to determine the prevalence of FVL mutation in normal subjects and in patients with VTE, as well as to measure the risk value of this mutation in developing VTE. First reports appeared in Europe, which concentrated on populations of Caucasian origin. They found FVL to be present in a quite high percentage of patients with VTE (15-65%) and healthy subjects (1-15%). Similar results were obtained when Caucasians were studied in non-European countries like USA, Australia and Israel. Table 1 gives examples of studies on FVL in European and non-European Caucasians. However, when studies where extended to other ethnic groups, FVL was surprisingly found to be very rare in Africans, South-East Asians, Chinese, Japanese, American Indians, Greenland Eskimos and Aboriginals of Australia (Table 2). These findings suggested that FVL might have occurred as a single event sometime in the distant past in a common European Caucasian ancestor, whose offspring are the present time Caucasian carriers of this mutation living in Europe and other countries. This assumption was later strengthened by molecular studies that reported FVL to be always associated with one haplotype of single nucleotides polymorphisms (SNPs), as will be discussed later. Later on, studies were conducted on
Table 1. Prevalence of FVL in Caucasian patients with VTE and normal subjects living in European and non-European countries. European countries on the Mediterranean Sea are shown.

| Country         | VTE patients (%) | Normal Population (%) | Reference |
|-----------------|------------------|------------------------|-----------|
| UK              | ---              | 1.74-5.6               | 19, 20    |
| Sweden          | 41.5-50          | 7.5-11.4               | 14, 15, 19|
| Poland          | ---              | 5                      | 21        |
| Netherlands     | 21               | 2                      | 10, 20    |
| Germany         | 30               | 7.1-12                 | 22, 23    |
| Belgium         | 22               | 3.3                    | 24        |
| Slovakia        | 29.5-37.0        | 4                      | 25, 26    |
| Austria         | 26               | ---                    | 27        |
| Hungary         | 44               | 6.9                    | 28, 29    |
| Serbia          | 29.9             | 5.8                    | 30        |
| Azerbaijan      | ---              | 14                     | 31        |
| Spain           | 9.2-26.3         | 1.6-5.8                | 32-37     |
| France          | 9-18             | 3.5-5.0                | 38-41     |
| Basques         | ---              | 0-0.7                  | 42, 43    |
| Italy           | 9.0-42.8         | 2-13.1                 | 12, 44-47 |
| Yugoslavia      | 15.5             | 4.0                    | 48        |
| Slovenia        | 12.9             | 6.3                    | 49        |
| Croatia         | 21.0-28.2        | 2.4-4.0                | 50-52     |
| Albania/Kosovo  | ---              | 3.4                    | 53        |
| Greece          | 16.2-31.9        | 2.5-7.0                | 2, 54-57  |
| USA             | 8.6              | 3.2-6.0                | 3, 16, 58 |
| Australia       | ---              | 4-10.2                 | 59-62     |
| Israel          | ---              | 4.3                    | 63        |
| Brazil          | 20               | 2                      | 64        |

Arabs and populations living in the Middle East and North Africa (The MENA region), as summarized in Table 3.\(^{31,63,79-133}\) These studies showed a high prevalence of FVL in these populations, who are not usually classified as Caucasians. However, the MENA region is geographically very close to Europe and had witnessed a lot of human movement from and to Europe, and hence such populations are expected to have some Caucasian genes in their DNA. Therefore, the presence of FVL in Arabs and North African populations should not be a surprising upshot.

**Factor V Leiden in the Mediterranean Region:**
Currently, there are 20 countries that have seacoasts on the Mediterranean Sea and therefore are called the Mediterranean countries; 5 are in North Africa, 4 in West Asia and 11 in South Europe. Figure 3 gives a map of the Mediterranean Sea and its countries, showing the prevalence of FVL in these countries which are based on the studies listed in tables 1 and 3. No data could be retrieved from the literature on prevalence of FVL in Libya, Malta, Bosnia or Montenegro. However, one study reported FVL in Yugoslav people which included patients and healthy subjects from all over the former Yugoslavia, and possibly some of their subjects were from Bosnia and Montenegro.\(^{48}\) There were no reports from Albania itself, but one study was conducted in Kosovo, the people of which are considered as Albanians.\(^{53}\) In Table 1, the prevalence of FVL in the people of the Basques was put separately, although not being a separate country, because of the unique rarity of FVL in these people.\(^{42,43}\) This has an important issue which will be discussed later. In Israel, the population consists of a mixture of Palestinian Arabs and other immigrants from different parts of the world, largely being of European Caucasian origin. Therefore, the results there were split between tables 1 and 3 according to the origin of the studied populations.

One may notice that the prevalence of FVL is present in its maximum peak in this part of the World. In addition, there is generally an Eas-to-West decline in prevalence of FVL in these countries. This observation was also noticed by Lucotte et al (2001) who also observed a South-to-North decline of these values in Europe, only when southwestern populations were excluded.\(^{134}\) These observations raised discussions in the literature on the exact place where FVL has first appeared.

**Has Factor V Leiden originated in the Eastern Mediterranean?** As was mentioned before, the first
Table 2. Prevalence of FVL in non-Caucasian patients with VTE and normal subjects in different parts of the world.

| Country/ Ethic groups | VTE patients (%) | Normal Population (%) | Reference |
|-----------------------|------------------|-----------------------|-----------|
| **Asians**            |                  |                       |           |
| Japan                 | 0                | 0                     | 65-68     |
| Korea                 | 0                | ---                   | 69        |
| China                 | 0                | 0                     | 70, 71    |
| Indonesia             | ---              | 0                     | 70        |
| Malaysia              | 0.5              | ---                   | 72        |
| Singapore             | 5                | ---                   | 72        |
| India                 | 3                | 1.3                   | 21, 73    |
| Pakistan              | 1.25             | ---                   | 74        |
| USA                   | ---              | 0                     | 75        |
| **Africans/ Black**   |                  |                       |           |
| Ethiopia              | ---              | 0                     | 70,76     |
| USA                   | 1.4              | 0.9                   | 58, 75    |
| Sub-Sahara            | ---              | 0                     | 70        |
| Ecuador               | ---              | 0                     | 70        |
| Venezuela             | ---              | 4.4                   | 77        |
| **Amerindians**       |                  |                       |           |
| Ecuador               | ---              | 0                     | 70        |
| Venezuela             | ---              | 1.25                  | 77        |
| USA                   | ---              | 0                     | 75        |
| **Eskimos**           |                  |                       |           |
| Greenland             | ---              | 0                     | 78        |
| **Indigenous Australians** |          |                       |           |
| Australia             | ---              | 0                     | 61        |

reports on the prevalence of FVL found high prevalence of FVL in European Caucasians, while the prevalence was almost zero in other ethnic groups. In addition, studies showed an association of FVL with one haplotype in all carriers of the mutation. Therefore, scientists got a perception that FVL has occurred once in the past time in one European Caucasian person. Anthropology proposes that Caucasoid populations who settled in Europe were diverted from Mongoloid populations (who moved to East Asia) around 32 thousands of years ago; therefore FVL should have appeared sometime earlier than 32,000 years ago.2,4,11,135-137 It was suggested that the mutation occurred in Europe first, and then spread to other parts of the world. However, the observed highest prevalence of FVL in Eastern Mediterranean countries have raised speculations that FVL might have occurred somewhere there and then spread to Europe.43,99,100,134,138,139 The author of this paper has found FVL to be associated with one haplotype in 67 Arabs from Eastern Mediterranean region, which was the same haplotype found in European carriers of the mutation, giving another confirmation that FVL occurred as a single event in the

Figure 3. Map of the Mediterranean Sea and its countries showing the prevalence of FVL in healthy populations living there.
past even in Arabs.\textsuperscript{140} Castoldi et al (1997) suggested that FVL probably occurred outside Europe.\textsuperscript{133} The rarity of FVL in the French and Spanish Basque populations, which are thought to be the oldest ethnic groups in Europe of Paleolithic origin, has also suggested FVL to occur outside Europe first.\textsuperscript{12,23} Lucotte et al (2001) proposed that FVL expanded in Europe during the Neolithic period, from a probable Anatolian center of origin in Turkey, which has occurred around 10,000 years ago.\textsuperscript{134} This may explain the highest prevalence of FVL in East Mediterranean countries, and that the prevalence decreases when radiating away from this region towards Europe or other parts of the world. Still, more genetic and molecular studies may be needed to detect certain genetic loci or markers that may help in following the movement of carriers of FVL in the Mediterranean region to definitely determine the exact location where FVL might have occurred first.

**Conclusions:** Molecular and epidemiological studies provide evidences that FVL should have occurred as a single event in the past. The Mediterranean region has the highest prevalence of FVL in the world. This suggests it as the area where this mutation has arisen, possibly 10,000 years ago, and then it was spread to other parts of the world.

**References:**

1. Dahlbäck B. Resistance to activated protein C, the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays. Pros and Cons. Thromb Haemost 73(5): 739-742, 1995. PMID:7482395
2. Rees DC, Cox M and Clegg JB. World distribution of factor V Leiden. Lancet 346(8983): 1133-1134, 1995. http://dx.doi.org/10.1016/S0140-6736(95)91803-5
3. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997;277:1305-1307 http://dx.doi.org/10.1001/jama.277.16.1305
4. Zivelin A, Griffin JH, Xu X, Pabinger I, Samama M, Conard J, Brenner B, Eldor A and Seligsohn U. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89(2): 397-402, 1997. PMID:9002940
5. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Bodijenko V, Chandy M, Dahlbäck B, Ginter EC, Miletić JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part I. Thromb Haemost. 76(5):651-662, 1996. PMID:8950768
6. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74(4): 1-6, 1995. PMID:8578439
7. Kane WH and Davie EW. Blood coagulation factor V and VIII: structural and functional similarities and their relationship to haemorrhagic and thrombotic disorders. Blood 71(3): 539-555, 1988. PMID:3125864
8. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880. PMID:7989361
9. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004-1008. http://dx.doi.org/10.1073/pnas.90.3.1004
10. Bertina RM, Koelmans BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde HD, van der Velden PA and Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475): 64-67, 1994. http://dx.doi.org/10.1038/369064a0
11. Dahlbäck B. Resistance to activated protein C caused by the factor V R506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost. 1997;55:59-64. http://dx.doi.org/10.1002/SJIC1096-

---

Table 3. Prevalence of FVL in patients with VTE and normal subjects in Arabs and non-Arabs living in different Middle-Eastern and North African countries. Countries on the Mediterranean Sea are shown.

| Country/ Ethnic groups | VTE patients (%) | Normal Population (%) | Reference |
|------------------------|-----------------|-----------------------|-----------|
| **North Africa**       |                 |                       |           |
| Morocco                | ---             | 0                     | 79-80     |
| Algeria                | 13.8            | 1.3-2.0               | 81, 82    |
| Tunisia                | 20.3-24.6       | 3.0-13.6              | 83-92     |
| Egypt                  | 30              | 2.5-10.2              | 93-97     |
| **Mediterranean**      |                 |                       |           |
| Palestine              | ---             | 11.7-27.2             | 63, 97, 98|
| (inside & outside Israel) |             |                       |           |
| Lebanon                | 9.9-70.6        | 13.6-18.7             | 89, 92, 99-106 |
| Syria                  | ---             | 13.6                  | 97, 99    |
| Turkey                 | 21-30.8         | 4.6-9.8               | 31, 107,108-115 |
| Cyprus                 | ---             | 13.4                  | 116       |
| **Middle East**        |                 |                       |           |
| Jordan                 | 23.9-25.7       | 10.5-27.2             | 97, 117-122|
| Iraq                   | ---             | 7.0                   | 123       |
| Kuwait                 | 15.8            | 2.4-5.5               | 97, 124   |
| Saudi Arabia           | ---             | 0-2.5                 | 89, 123, 125 |
| Bahrain                | 52              | 3.1-14.7              | 89, 126   |
| Oman                   | 0               | 0                     | 127       |
| Yemen                  | ---             | 0                     | 63        |
| Iran                   | 11.4            | 2.0-10.6              | 123, 128-133 |

---

Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
13. Hoagland LE, Tripplet DA, Peng F, et al. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method. Thromb Res. 1996;83:363-373.

14. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524. http://dx.doi.org/10.1093/jcb/117.6.PM1d:798612 PMCid:330087

15. Alderborn A, Siegbahn A, Wadelius C. Venous thrombosis: factor V G1691A genotyping related to APC resistance measured by 2 methods. Eur J Haematol. 1997;58:229-232. http://dx.doi.org/10.1111/j.1600-0609.1997.tb01659.x

16. Bontempo FA, Hassett AC, Faruki H, et al. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg. 1997;25(2):271-275. http://dx.doi.org/10.1016/S0741-5214(97)00348-3

17. Florell SR, Rodgers GM. Inherited thrombotic disorders: An update. Am J Hematol. 1997;54:53-60. http://dx.doi.org/10.1002/SICJ1096- 8652(199705)54:1<53:AID-AJH8>3.0.CO;2-2

18. Samama MM, Simon D, Horlöeue MH, et al. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis. 1996;26:315-330. PMid:897137

19. Bengtsson A, Zöller B, de Frutos PG, Dahlbäck B and Sturfelt G. APC-resistance as carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000:85:1271-1276 PMid:11114134

20. González Ordóñez AJ, Medina Rodriguez JM, Martín L, Alvarez V, Coto E and Vargas M. Blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul Fibrinolysis. 1999; 10: 303-307 http://dx.doi.org/10.1097/00001721-1999100700-00013

21. Pullmann R, Kubisz P. Factor V Leiden and the Slovak population. Gen Physiol Biophys. 2004;23:435-442 PMid:15815078

22. Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. APC-resistance as determined by FXa assay in the same factor V gene mutation in 47 out of 50 thrombosis-prone families. Thromb Res. 1996;83:363-373.

23. Hainaut P, Azerad MA, Lehmann E, Schlit AF, Zech F, Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. APC-resistance as determined by FXa assay in the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524. http://dx.doi.org/10.1093/jcb/117.6.PM1d:798612 PMCid:330087

24. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3

25. Marrion P, Karbeck JL, Hunter DJ, et al. Clinical comments on genetic marker prevalence (factor V Leiden, prothrombin 20210A and homozygous methylenetetrahydrofolate reductase variant [H/MTHFR]): based on a study conducted in Health Department No. 19 of the Valencian Community. Rev Clin Esp. 2007;207:26-28 PMid:17306151

26. Samama MM, Simon D, Horlöeue MH, et al. Diagnosis and clinical characteristics of inherited activated protein C resistance. Haemostasis. 1996;26:315-330. PMid:897137

27. Bengtsson A, Zöller B, de Frutos PG, Dahlbäck B and Sturfelt G. APC-resistance as carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica. 2000:85:1271-1276 PMid:11114134

28. González Ordóñez AJ, Medina Rodriguez JM, Martín L, Alvarez V, Coto E and Vargas M. Blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul Fibrinolysis. 1999; 10: 303-307 http://dx.doi.org/10.1097/00001721-1999100700-00013

29. Pullmann R, Kubisz P. Factor V Leiden and the Slovak population. Gen Physiol Biophys. 2004;23:435-442 PMid:15815078

30. Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. APC-resistance as determined by FXa assay in the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524. http://dx.doi.org/10.1093/jcb/117.6.PM1d:798612 PMCid:330087

31. Hainaut P, Azerad MA, Lehmann E, Schlit AF, Zech F, Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. APC-resistance as determined by FXa assay in the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524. http://dx.doi.org/10.1093/jcb/117.6.PM1d:798612 PMCid:330087

32. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3

33. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3

34. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3

35. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3

36. Herrmann FH, Koessler M, Schroder W, Altman R, Jimenez Bonilla R, Lopaciuk S, Perez-Requejo JL and Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol. 1994;14(4):403-11, 1997. http://dx.doi.org/10.1002/SICJ1096- 8652(1997)14:4<403:AID-GEPIS>3.0.CO;2-3
58. Hatzaki A, Anagnostopoulou E, Metaxa-Mariatou V, Melissinos Mekaj Y, Zhubi B, Hoxha H, Belegu R, Mekaj A, Miftari E, Coen D, Zadro R, Honović L, Banfić L, Stavljenić R Cikes V, Abaza I, Krzelj V, Terzić IM, Tafra R, Trlaja A, Bedencic M, Bozic M, Peternel P, Stegnar M. Major and Mikovic D, Rakicevic L, Kovac M, Radojkovic D. Prevalence of Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Gessoni G, Valverde S, Canistro R, Manoni F. Factor V Leiden Sottilotta G, Mammì C, Furlò G, Oriana V, Latella C, Trapani precoagulation tests in patients with venous thrombosis, their blood relatives and the general population. Blood. 2010;10:193-195 PMID:20671880 PMCID:2906187
59. Bennett JA, Palmer LJ, Musk AW, Erber WN. Prevalence of factor V Leiden and prothrombin 20210A mutations in indigenous Australians. Thromb Haemost. 2001;86:1592-1593 PMID:11776339

60. Gibson CS, MacLennan AH, Radzki Z, Hague WM, Haan EA, Sharpe P, Priest K, Chan A, Dekker GA; South Australian Cerebral Palsy Research Group. The prevalence of inherited thrombophilias in a Caucasian Australian population. Pathology. 2005;37:160-163 http://dx.doi.org/10.1080/00313020500582520 PMID:16028846

61. Rosen E, Reihlen P, Heyd J, Levy-Lahad E. High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost. 1999;82:78-79 http://dx.doi.org/10.1159/000203548 PMID:9210909

62. Koida H, Ishida F, Scimodaira S, Takamiya O, Furihata K, Kitano K. Resistance to activated protein C and Arg506Gln factor V mutation are uncommon in eastern Asian populations. Acta Haematol. 1995;98:22-25 http://dx.doi.org/10.1159/000203548 PMID:15262837

63. Fujimura H, Kambayashi J, Mondon M, Kato H, Miyata T. Coagulation factor V Leiden may have a racial background. Thromb Haemost. 1995;74:1381-1382 PMID:8607128

64. Ro A, Haru M, Takada A. The Factor V Leiden and factor V Leiden and factor II G20210A mutations in a Brazilian population of non-European ancestry. Thromb Haemost. 1999;82:1769

65. Kim TW, Kim WK, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Seo EJ, Chi HS, Kim SH. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78 http://dx.doi.org/10.1002/ajh.2830490312 PMID:8607128

66. Zama T, Murata M, Ono F, Watanabe K, Watanabe R, Moriki T, Yokoyama K, Tokuhira M, Beda Y. Low prevalence of activated protein C resistance and factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78 http://dx.doi.org/10.1002/ajh.2830490312 PMID:8607128

67. Fujimura H, Kambayashi J, Mondon M, Kato H, Miyata T. Coagulation factor V Leiden may have a racial background. Thromb Haemost. 1995;74:1381-1382 PMID:8607128

68. Ro A, Haru M, Takada A. The Factor V Leiden and factor V Leiden and factor II G20210A mutations in a Brazilian population of non-European ancestry. Thromb Haemost. 1999;82:1769

69. Kim TW, Kim WK, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Seo EJ, Chi HS, Kim SH. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78 http://dx.doi.org/10.1002/ajh.2830490312 PMID:8607128

70. Zama T, Murata M, Ono F, Watanabe K, Watanabe R, Moriki T, Yokoyama K, Tokuhira M, Beda Y. Low prevalence of activated protein C resistance and factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Hematol. 1996;65:71-78 http://dx.doi.org/10.1002/ajh.2830490312 PMID:8607128

71. Fujimura H, Kambayashi J, Mondon M, Kato H, Miyata T. Coagulation factor V Leiden may have a racial background. Thromb Haemost. 1995;74:1381-1382 PMID:8607128
Klai S, Fekih-Mrissa N, Rachdi R, Gritli N. The status of factor V Leiden mutation. Lancet. 1996;347:58-60.

Zammiti W, Mtiraoui N, Mercier E, Abboud N, Saidi S, Maalej L, Hadjkacem B, Ben Amor I, Smaoui M, Gargouri A, Ajem A, Slama A, Slama FB, Mehjoub T. Prevalence of factor V Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon. Am J Hematol. 2006;81:641-643. http://dx.doi.org/10.1002/ajh.20582 PMid:16823828

El-Karaky H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, Moshen NA, Korb M, El-Raziky M, El-Sonouk MA, A-Kader H. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol. 2004;83:712-715. http://dx.doi.org/10.1007/s00277-004-0921-4 PMid:15309526

Abu-Skeen IA, Mohamed AA, Moustafa NN, Badawy ME. Factor V Leiden and prothrombin G20210A gene mutations in women with a history of thrombosis during pregnancy. Relation to pregnancy outcomes for mother and fetus. Saudi Med J. 2010;31:123-129 PMid:20174725

Maher MM, Soloma SH. Assessment of thrombophilic abnormalities during the active state of inflammatory bowel disease. Saudi J Gastroenterol. 2008;14:192-197. http://dx.doi.org/10.1016/j.sjg.2007.12.006 PMid:18605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

Inani-Hakime N, Tamim H, Elias G, Finan RR, Daccache JL, Almawi WY. High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean. Clin Chem. 2000;46:134-136. PMid:10876267

Taher A, Khalil I, Shamseddine A, El-Ahbab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost. 2001;86:723-724 PMid:11520257

Taher A, Finan RR, Almawi WY. Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, in a recurrent miscarriage population. Ann Hematol. 2002;71:300-305. http://dx.doi.org/10.1007/s00277-002-0515-9 PMid:1210223

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623

http://dx.doi.org/10.1016/j.ajh.2010.04.017 PMid:20605623
139. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-99

http://dx.doi.org/10.1016/j.ymgme.2005.04.002 PMid:16185908

140. Jadaon MM, Dashti AA, Lewis HL. What is the origin of factor V Leiden mutation in Arabs? The first molecular proof. J Thromb Haemost. 2011;9: P-MO-155.